Outcome of corticosteroid administration in autoimmune pulmonary alveolar proteinosis: A retrospective cohort study

BMC Pulmonary Medicine

Volumn 15, Issue 1, 2015, Pages

  Akasaka, Keiichi ^a   Tanaka, Takahiro ^a   Kitamura, Nobutaka ^a   Ohkouchi, Shinya ^b   Tazawa, Ryushi ^a   Takada, Toshinori ^a   Ichiwata, Toshio ^c   Yamaguchi, Etsuro ^d   Hirose, Masaki ^e   Arai, Toru ^e   Nakano, Kentaro ^f   Nei, Takahito ^g   Ishii, Haruyuki ^h   Handa, Tomohiro ⁱ   Inoue, Yoshikazu ^e   Nakata, Koh ^a  

^a NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

^d AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^f DOKKYO MEDICAL UNIVERSITY   (Japan)

^g NIPPON MEDICAL SCHOOL   (Japan)

^h KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY; METHYLPREDNISOLONE; PREDNISOLONE; AUTOANTIBODY; GLUCOCORTICOID;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE LUNG ALVEOLUS PROTEINOSIS; CAUSE OF DEATH; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CORTICOSTEROID THERAPY; DISEASE COURSE; DISEASE SEVERITY ASSESSMENT; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; HUMAN; INVASIVE ASPERGILLOSIS; LOW DRUG DOSE; LUNG ALVEOLUS PROTEINOSIS; MALE; PROGNOSIS; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT DURATION; TREATMENT WITHDRAWAL; VERY ELDERLY; ADOLESCENT; AUTOIMMUNE DISEASES; DOSE RESPONSE; FOLLOW UP; IMMUNOLOGY; MIDDLE AGED; PULMONARY ALVEOLAR PROTEINOSIS; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PREDNISOLONE; PULMONARY ALVEOLAR PROTEINOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84938840431     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/s12890-015-0085-0     Document Type: Article

References (41)

1. Rosen SH, Castleman B, Liebow AA. Pulmonary alveolar proteinosis. N Engl J Med. 1958;258:1123-42.
2. Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med. 2003;349:2527-39.
3. Bewig B, Wang XD, Kirsten D, Dalhoff K, Schäfer H. GM-CSF and GM-CSF βc receptor in adult patients with pulmonary alveolar proteinosis. Eur Respir J. 2000;15:350-7.
4. Suzuki T, Sakagami T, Rubin BK, Nogee LM, Wood RE, Zimmerman SL, et al. Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA. J Exp Med. 2008;205:1292-304.
5. Suzuki T, Maranda B, Sakagami T, Catellier P, Couture CY, Carey BC, et al. Hereditary pulmonary alveolar proteinosis caused by recessive CSF2RB mutations. Eur Respir J. 2011;37:201-4.
6. Ishii H, Tazawa R, Kaneko C, Saraya T, Inoue Y, Hamano E, et al. Clinical features of secondary pulmonary alveolar proteinosis: pre-mortem cases in Japan. Eur Respir J. 2011;37:465-8.
7. Kitamura T, Tanaka N, Watanabe J, Uchida K, Kanegasaki S, Yamada Y, et al. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med. 1999;190:875-80.
8. Inoue Y, Trapnell BC, Tazawa R, Arai T, Takada T, Hizawa N, et al. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med. 2008;177:752-62.
9. Sakagami T, Uchida K, Suzuki T, Carey BC, Wood RE, Wert SE, et al. Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosis. N Engl J Med. 2009;361:2679-81.
10. Uchida K, Nakata K, Trapnell BC, Terakawa T, Hamano E, Mikami A, et al. High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood. 2004;103:1089-98.
11. Morgan C. The benefits of whole lung lavage in pulmonary alveolar proteinosis. Eur Respir J. 2004;23:503-5.
12. Beccaria M, Luisetti M, Rodi G, Corsico A, Zoia MC, Colato S, et al. Long-term durable benefit after whole lung lavage in pulmonary alveolar proteinosis. Eur Respir J. 2004;23:526-31.
13. Bonella F, Bauer PC, Griese M, Wessendorf TE, Guzman J, Costabel U. Wash-out kinetics and efficacy of a modified lavage technique for alveolar proteinosis. Eur Respir J. 2012;40:1468-74.
14. Dranoff G, Crawford AD, Sadelain M, Ream B, Rashid A, Bronson RT, et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science. 1994;264:713-6.
15. Stanley E, Lieschke GJ, Grail D, Metcalf D, Hodgson G, Gall JA, et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci U S A. 1994;91:5592-6.
16. Wylam ME, Ten R, Prakash UB, Nadrous HF, Clawson ML, Anderson PM. Aerosol granulocyte-macrophage colony-stimulating factor for pulmonary alveolar proteinosis. Eur Respir J. 2006;27:585-93.
17. Tazawa R, Trapnell BC, Inoue Y, Arai T, Takada T, Nasuhara Y, et al. Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 2010;181:1345-54.
18. Ohashi K, Sato A, Takada T, Arai T, Kasahara Y, Hojo M, et al. Reduced GM-CSF autoantibody in improved lung of autoimmune pulmonary alveolar proteinosis. Eur Respir J. 2012;39:777-80.
19. Gallin J, Goldstein L, Snyderman R. Inflammation: Basic principles and clinical correlates. 2nd ed. New York: Raven Press; 1992. p. 1-4.
20. Saxon A, Stevens RH, Ramer SJ, Clements PJ, Yu DT. Glucocorticoids administered in vivo inhibit human suppressor T lymphocyte function and diminish B lymphocyte responsiveness in in vitro immunoglobulin synthesis. J Clin Invest. 1978;61:922-30.
21. Andréau K, Lemaire C, Souvannavong V, Adam A, Andréau K. Induction of apoptosis by dexamethasone in the B cell lineage. Immunopharmacology. 1998;40:67-76.
22. Rinehart JJ, Sagone AL, Balcerzak SP, Ackerman GA, LoBuglio AF. Effects of corticosteroid administration on human monocyte function. N Engl J Med. 1975;292:236-41.
23. Belayat F, Meniai K, Michaux C, Kafidi N, Coignoul F, Dewaele A. In vitro effect of glucocorticoids on phagocytic function of sheep alveolar macrophages. Vet J. 1998;155:177-81.
24. Linden M, Brattsand R. Effects of a corticosteroid, budesonide, on alveolar macrophage and blood monocyte secretion of cytokines: differential sensitivity of GM-CSF, IL-1 beta, and IL-6. Pulm Pharmacol. 1994;7:43-7.
25. Davidson JM, Macleod WM. Pulmonary alveolar proteinosis. Br J Dis Chest. 1969;63:13-28.
26. Punatar AD, Kusne S, Blair JE, Seville MT, Vikram HR. Opportunistic infections in patients with pulmonary alveolar proteinosis. J Infect. 2012;65:173-9.
27. Postle AD, Warner JO. Steroids, surfactant and lung disease. Thorax. 1996;51:880-1.
28. Du Bois RM, McAllister WA, Branthwaite MA. Alveolar proteinosis: diagnosis and treatment over a 10-year period. Thorax. 1983;38:360-3.
29. Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med. 2002;166:215-35.
30. Uchida K, Nakata K, Carey B, Chalk C, Suzuki T, Sakagami T, et al. Standardized serum GM-CSF autoantibody testing for the routine clinical diagnosis of autoimmune pulmonary alveolar proteinosis. J Immunol Methods. 2014;402:57-70.
31. Kitamura T, Uchida K, Tanaka N, Tsuchiya T, Watanabe J, Yamada Y, et al. Serological diagnosis of idiopathic pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 2000;162:658-62.
32. Ramirez J. Pulmonary alveolar proteinosis: a new technique and rationale for treatment. Arch Intern Med. 1963;112:419-31.
33. Robertson HE. Pulmonary alveolar proteinosis. Can Med Assoc J. 1965;93:980-3.
34. Griese M, Ripper J, Sibbersen A, Lohse P, Lohse P, Brasch F, et al. Long-term follow-up and treatment of congenital alveolar proteinosis. BMC Pediatr. 2011;11:72.
35. Ishii H, Seymour JF, Tazawa R, Inoue Y, Uchida N, Nishida A, et al. Secondary pulmonary alveolar proteinosis complicating myelodysplastic syndrome results in worsening of prognosis: a retrospective cohort study in Japan. BMC Pulm Med. 2014;14:37.
36. Luisetti M, Rodi G, Perotti C, Campo I, Mariani F, Pozzi E, et al. Plasmapheresis for treatment of pulmonary alveolar proteinosis. Eur Respir J. 2009;33:1220-2.
37. Borie R, Debray MP, Laine C, Aubier M, Crestani B. Rituximab therapy in autoimmune pulmonary alveolar proteinosis. Eur Respir J. 2009;33:1503-6.
38. Kavuru MS, Malur A, Marshall I, Barna BP, Meziane M, Huizar I, et al. An open-label trial of rituximab therapy in pulmonary alveolar proteinosis. Eur Respir J. 2011;38:1361-7.
39. Kobayashi T, Ebina M, Oshima M, Shimizu M, Uchiyama M, Saijo Y, et al. Case of alveolar proteinosis associated with pulmonary aspergillosis. Nippon Naika Gakkai Zasshi. 1999;88:135-7.
40. Yamaguchi S, Takayanagi N, Tokunaga D, Sugita Y, Kawabata Y. A case of pulmonary alveolar proteinosis which initially deteriorated rapidly with worsening of pulmonary nocardiosis, responded promptly to treatment of the pulmonary nocardiosis. Nihon Kokyuki Gakkai Zasshi. 2010;48:580-3.
41. Morinari H, Terashi R, Okubo S, Homma S, Tanaka M. Remission of pulmonary alveolar proteinosis during antituberculous chemoadministration. Eur J Respir Dis. 1987;71:54-5.